Abstract
Tripartite motif protein 5-alpha (TRIM5α) is a cytoplasmic protein that efficiently recognizes the incoming capsid (CA) protein of retroviruses and potently inhibits virus infection in a species-specific manner. Through directly recognizing and interacting with HIV CA, TRIM5α is capable of disrupting the ordered process of viral uncoating, eventually interfering with HIV-1 reverse transcription and virus replication. TRIM5α protein contains four domains: RING domain, B-box 2 domain, coiled-coil domain, and B30.2 domain (SPRY) domain. All of the domains are necessary for efficient retrovirus restriction and the B30.2 domain has been shown to be the determinant of the specificity of restriction. Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutics. Various mutants of TRIM5α have been described which differently affect the HIV-1 reverse transcription process. This makes the establishment of new and improved models for HIV replication and AIDS pathogenesis by monitoring endogenous TRIM5α an attractive approach. TRIM5α-mediated restriction is modulated by the host protein Cyclophilin A (Cyp A) which could effectively interact with the CA of HIV-1. Here we will review the structure and roles of TRIM5α protein, the interaction between Cyp A and TRIM5α, as well as gene therapy strategies associated with TRIM5α to inhibit HIV-1 infection.
Keywords: TRIM5α, Cyp A, HIV-1, mechanism, gene therapy, Tripartite motif protein 5-alpha, cytoplasmic protein, CA, viral uncoating, RING domain
Current Medicinal Chemistry
Title: Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication
Volume: 18 Issue: 17
Author(s): Jing Zhang, Weiying Ge, Peng Zhan, Erik De Clercq and Xinyong Liu
Affiliation:
Keywords: TRIM5α, Cyp A, HIV-1, mechanism, gene therapy, Tripartite motif protein 5-alpha, cytoplasmic protein, CA, viral uncoating, RING domain
Abstract: Tripartite motif protein 5-alpha (TRIM5α) is a cytoplasmic protein that efficiently recognizes the incoming capsid (CA) protein of retroviruses and potently inhibits virus infection in a species-specific manner. Through directly recognizing and interacting with HIV CA, TRIM5α is capable of disrupting the ordered process of viral uncoating, eventually interfering with HIV-1 reverse transcription and virus replication. TRIM5α protein contains four domains: RING domain, B-box 2 domain, coiled-coil domain, and B30.2 domain (SPRY) domain. All of the domains are necessary for efficient retrovirus restriction and the B30.2 domain has been shown to be the determinant of the specificity of restriction. Species-specific innate resistance against viral infections offers novel avenues for antiviral therapeutics. Various mutants of TRIM5α have been described which differently affect the HIV-1 reverse transcription process. This makes the establishment of new and improved models for HIV replication and AIDS pathogenesis by monitoring endogenous TRIM5α an attractive approach. TRIM5α-mediated restriction is modulated by the host protein Cyclophilin A (Cyp A) which could effectively interact with the CA of HIV-1. Here we will review the structure and roles of TRIM5α protein, the interaction between Cyp A and TRIM5α, as well as gene therapy strategies associated with TRIM5α to inhibit HIV-1 infection.
Export Options
About this article
Cite this article as:
Zhang Jing, Ge Weiying, Zhan Peng, De Clercq Erik and Liu Xinyong, Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication, Current Medicinal Chemistry 2011; 18 (17) . https://dx.doi.org/10.2174/092986711795933687
DOI https://dx.doi.org/10.2174/092986711795933687 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sevoflurane Post-treatment Mitigates Oxygen-glucose Deprivationinduced
Pyroptosis of Hippocampal Neurons by Regulating the
Mafb/DUSP14 Axis
Current Neurovascular Research Mechanisms of Hormonal Regulation of Sertoli Cell Development and Proliferation: A Key Process for Spermatogenesis
Current Molecular Pharmacology Sample Treatment in Organic Compound Determination: A Green Chemistry Perspective
Current Green Chemistry Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Discovery of Notch-Sparing γ-Secretase Inhibitors
Current Alzheimer Research Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Evolution of Resistance to Cancer Therapy
Current Pharmaceutical Design Enhanced Topical Delivery of Cyclosporin-A Using PLGA Nanoparticles as Carrier
Current Nanoscience Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics P-Glycoprotein Contributes to Cell Membrane Depolarization of Hippocampus and Neocortex in a Model of Repetitive Seizures Induced by Pentylenetetrazole in Rats
Current Pharmaceutical Design Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry Endothelial Cell Adhesion Molecules and Cancer Progression
Current Medicinal Chemistry Insight into the Structural Requirements of Narlaprevir-Type Inhibitors of NS3/NS4A Protease Based on HQSAR and Molecular Field Analyses
Combinatorial Chemistry & High Throughput Screening HIV/AIDS Curability Study, Different Approaches and Drug Combination
Infectious Disorders - Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued)